trending Market Intelligence /marketintelligence/en/news-insights/trending/UGx74j4746v2i-UgH4Devg2 content esgSubNav
In This List

PDL BioPharma raises common stock, note repurchase authorization to $275M

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


PDL BioPharma raises common stock, note repurchase authorization to $275M

PDL BioPharma Inc.'s board has authorized the repurchase of up to $275 million of common stock and convertible notes, an increase of $75 million from the prior authorization.

PDL, which acquires, manages, and commercializes commercial-stage pharmaceutical assets and late-clinical-stage pharmaceutical products, initially authorized $200 million for the buyback of shares and notes.

On Dec. 13, the company said it had entered a private agreement to exchange 80% of its outstanding 2.75% convertible senior notes due Dec. 2021 and Dec. 2024 for $98 million in cash and 13.4 million of its common shares.

The cash and common stock to be distributed by PDL in this exchange will utilize about $143.8 million of the original $200 million authorization.